BIYKEM BOZKURT to Anti-Obesity Agents
This is a "connection" page, showing publications BIYKEM BOZKURT has written about Anti-Obesity Agents.
Connection Strength
0.697
-
Designing Next-Generation Cardiometabolic Outcome Trials for Obesity Medicines. J Am Coll Cardiol. 2026 Apr 21; 87(15):1936-1949.
Score: 0.236
-
Baseline characteristics in the SYNCHRONIZE?-2 randomized phase 3 trial of survodutide, a glucagon receptor/GLP-1 receptor dual agonist, for obesity in people with type 2 diabetes. Diabetes Obes Metab. 2026 Feb; 28(2):1490-1498.
Score: 0.231
-
Survodutide for treatment of obesity: Baseline characteristics of participants in a randomized, double-blind, placebo-controlled, phase 3 trial (SYNCHRONIZE?-1). Diabetes Obes Metab. 2026 Jan; 28(1):337-346.
Score: 0.230